

# Vogliviga M 0.3 Tablet

**Composition (per tablet):**

Metformin Hydrochloride (500mg) SR + Voglibose (0.3mg)

**Description:**

Vogliviga M 0.3 Tablet is a combination oral antidiabetic medication that helps manage blood glucose levels in patients with type 2 diabetes mellitus. Metformin acts as an insulin sensitizer and reduces hepatic glucose production, while Voglibose is an alpha-glucosidase inhibitor that delays intestinal carbohydrate absorption, thereby reducing postprandial glucose spikes.

**Indications:**

- Type 2 Diabetes Mellitus
- Inadequate response to Metformin monotherapy
- Management of elevated postprandial glucose levels

**Mechanism of Action:**

Metformin enhances peripheral insulin sensitivity and inhibits hepatic gluconeogenesis. Voglibose inhibits intestinal enzymes responsible for breaking down complex carbohydrates, slowing glucose absorption and minimizing post-meal hyperglycemia.

**Dosage and Administration:**

One tablet to be taken once or twice daily with meals or as directed by a physician. Dosage should be adjusted according to the patient's blood glucose levels and clinical response.

**Contraindications:**

- Severe renal impairment
- Diabetic ketoacidosis
- Hypersensitivity to any of the components
- Gastrointestinal disorders like inflammatory bowel disease or obstruction

**Precautions:**

Monitor renal function regularly. Caution in elderly, liver dysfunction, and those on alcohol. Educate patients about the signs of lactic acidosis.

**Side Effects:**

- Gastrointestinal disturbances (nausea, bloating, diarrhea)
- Flatulence
- Rare: Lactic acidosis (Metformin-related, serious)
- Abdominal discomfort

**Storage:**

Store in a cool and dry place below 30°C. Protect from moisture and direct sunlight. Keep out of reach of children.

Manufactured in India for:



**Cafoli Lifecare Pvt. Ltd.**

**(An ISO 9001: 2015 Certified Co.)**

Plot no.: 367-FF, Industrial Area Phase-I,

Panchkula-134113

TM: Trademark Applied for